Can a gout drug help lung cancer treatment reach the brain?
NCT ID NCT07485452
First seen Apr 08, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase how much of the cancer drug gets into the brain fluid. Only 7 patients with EGFR-mutated lung cancer and no brain metastases will take part. The goal is to measure drug levels, not to treat the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus MC
Rotterdam, Netherlands
-
Maastricht UMC+
Maastricht, Netherlands
Contact Phone: •••-•••-••••
-
The Netherlands Cancer Institute
Amsterdam, Netherlands
Conditions
Explore the condition pages connected to this study.